

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 4.0      Revision Date: 2021/04/09      SDS Number: 4944869-00004      Date of last issue: 2020/10/10  
Date of first issue: 2019/09/30

### 1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

#### Supplier's company name, address and phone number

Company name of supplier : Organon & Co.

Address : 30 Hudson Street, 33rd floor  
Jersey City, New Jersey, U.S.A 07302

Telephone : 551-430-6000

E-mail address : EHSSTEWARD@organon.com

Emergency telephone number : 215-631-6999

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

### 2. HAZARDS IDENTIFICATION

#### GHS classification of chemical product

Serious eye damage/eye irritation : Category 2

Reproductive toxicity : Category 1A

Specific target organ toxicity - repeated exposure : Category 2 (Kidney, Parathyroid gland)

Short-term (acute) aquatic hazard : Category 3

Long-term (chronic) aquatic hazard : Category 3

#### GHS label elements

Hazard pictograms :

Signal word : Danger

Hazard statements : H319 Causes serious eye irritation.  
H360D May damage the unborn child.  
H373 May cause damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.  
H412 Harmful to aquatic life with long lasting effects.

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 4.0      Revision Date: 2021/04/09      SDS Number: 4944869-00004      Date of last issue: 2020/10/10  
Date of first issue: 2019/09/30

### Precautionary statements

**Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe dust.  
P264 Wash skin thoroughly after handling.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**  
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
P337 + P313 If eye irritation persists: Get medical advice/ attention.

**Storage:**  
P405 Store locked up.

**Disposal:**  
P501 Dispose of contents/ container to an approved waste disposal plant.

### Other hazards which do not result in classification

Important symptoms and outlines of the emergency assumed : May form explosible dust-air mixture if dispersed. Contact with dust can cause mechanical irritation or drying of the skin.

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
Cellulose	9004-34-6	>= 30 - < 40	
Starch	9005-25-8	>= 30 - < 40	8-98
Olmesartan	144689-63-4	>= 10 - < 20	
Hydrochlorothiazide	58-93-5	>= 1 - < 10	
Amlodipine Besylate	652969-01-2	>= 2.5 - < 10	

## 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version 4.0      Revision Date: 2021/04/09      SDS Number: 4944869-00004      Date of last issue: 2020/10/10  
Date of first issue: 2019/09/30

---

- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
If easy to do, remove contact lens, if worn.  
Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Causes serious eye irritation.  
May damage the unborn child.  
May cause damage to organs through prolonged or repeated exposure.  
Contact with dust can cause mechanical irritation or drying of the skin.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.
- 

### 5. FIREFIGHTING MEASURES

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : High volume water jet
- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Do not use a solid water stream as it may scatter and spread fire.  
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Chlorine compounds  
Sulphur oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment : In the event of fire, wear self-contained breathing apparatus.
-

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/10/10
4.0	2021/04/09	4944869-00004	Date of first issue: 2019/09/30

for firefighters

Use personal protective equipment.

### 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 7. HANDLING AND STORAGE

#### Handling

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing. Do not breathe dust. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version 4.0      Revision Date: 2021/04/09      SDS Number: 4944869-00004      Date of last issue: 2020/10/10  
Date of first issue: 2019/09/30

Avoidance of contact : Oxidizing agents  
Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### Storage

Conditions for safe storage : Keep in properly labelled containers.  
Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.  
Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents  
Packaging material : Unsuitable material: None known.

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Threshold limit value and permissible exposure limits for each component in the work environment

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH
Starch	9005-25-8	TWA	10 mg/m <sup>3</sup>	ACGIH
Olmesartan	144689-63-4	TWA	30 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	300 µg/100 cm <sup>2</sup>	Internal
Hydrochlorothiazide	58-93-5	TWA	100 µg/m <sup>3</sup> (OEB 2)	Internal
Amlodipine Besylate	652969-01-2	TWA	20 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal

**Engineering measures** : Use feasible engineering controls to minimize exposure to compound.  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.  
Filter type : Particulates type  
Hand protection :  
Material : Chemical-resistant gloves

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 2020/10/10
4.0	2021/04/09	4944869-00004	Date of first issue: 2019/09/30

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state : tablet

Colour : No data available

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Boiling point, initial boiling point and boiling range : No data available

Flammability (solid, gas) : No data available

Flammability (liquids) : No data available

Lower explosion limit and upper explosion limit / flammability limit  
Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Flash point : No data available

Decomposition temperature : No data available

pH : No data available

Evaporation rate : Not applicable

Auto-ignition temperature : No data available

Viscosity  
Viscosity, kinematic : Not applicable

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Vapour pressure : Not applicable

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 4.0      Revision Date: 2021/04/09      SDS Number: 4944869-00004      Date of last issue: 2020/10/10  
Date of first issue: 2019/09/30

---

Density and / or relative density  
Relative density : No data available

Density : No data available

Relative vapour density : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics  
Particle size : No data available

---

### 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Dust can form an explosive mixture in air.  
Can react with strong oxidizing agents.

Conditions to avoid : Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

### 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

#### Components:

##### Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

---

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 4.0      Revision Date: 2021/04/09      SDS Number: 4944869-00004      Date of last issue: 2020/10/10  
Date of first issue: 2019/09/30

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

### Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

### Olmesartan:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 2,000 mg/kg

LD50 (Dog): > 1,500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

### Hydrochlorothiazide:

Acute oral toxicity : LD50 (Rat): > 2,750 mg/kg

LD50 (Mouse): > 2,830 mg/kg

Acute toxicity (other routes of administration) : LD50 (Rat): 990 mg/kg  
Application Route: Intravenous

LD50 (Mouse): 590 mg/kg

Application Route: Intravenous

### Amlodipine Besylate:

Acute oral toxicity : LD50 (Rat): 393 mg/kg

### Skin corrosion/irritation

Not classified based on available information.

### Components:

#### Olmesartan:

Remarks : No data available

#### Hydrochlorothiazide:

Species : Rabbit

Result : No skin irritation

### Serious eye damage/eye irritation

Causes serious eye irritation.



# Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/10/10
4.0	2021/04/09	4944869-00004	Date of first issue: 2019/09/30

---

**Components:****Starch:**

Species	:	Rabbit
Result	:	No eye irritation

**Olmesartan:**

Species	:	Rabbit
Result	:	Moderate eye irritation
Method	:	Draize Test

**Hydrochlorothiazide:**

Species	:	Rabbit
Result	:	Mild eye irritation

**Amlodipine Besylate:**

Species	:	Rabbit
Result	:	Severe irritation

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****Starch:**

Test Type	:	Maximisation Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Result	:	negative

**Olmesartan:**

Exposure routes	:	Skin contact
Remarks	:	No data available

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Cellulose:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
	:	Result: negative
	:	Test Type: In vitro mammalian cell gene mutation test
	:	Result: negative

# Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/10/10
4.0	2021/04/09	4944869-00004	Date of first issue: 2019/09/30

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Starch:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

**Olmesartan:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Mutagenicity (in vitro mammalian cytogenetic test)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Test system: Chinese hamster lung cells  
Result: positive

Test Type: Mouse Lymphoma  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

**Hydrochlorothiazide:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster ovary cells  
Result: negative

Test Type: sister chromatid exchange assay  
Test system: Chinese hamster ovary cells  
Result: positive

Test Type: in vitro assay  
Test system: mouse lymphoma cells  
Result: positive

Genotoxicity in vivo : Test Type: Chromosomal aberration

**Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2020/10/10
4.0	2021/04/09	4944869-00004	Date of first issue: 2019/09/30

	Species: Chinese hamster
	Cell type: Bone marrow
	Result: negative
	Test Type: in vivo assay
	Species: Mouse
	Cell type: Bone marrow
	Result: negative
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

**Amlodipine Besylate:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
	Result: negative
	Test Type: Chromosome aberration test in vitro
	Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:**
**Cellulose:**

Species	: Rat
Application Route	: Ingestion
Exposure time	: 72 weeks
Result	: negative

**Olmesartan:**

Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
Result	: negative

Species	: Mouse
Application Route	: Oral
Exposure time	: 6 Months
Result	: negative

**Hydrochlorothiazide:**

Species	: Mouse, female
Application Route	: Oral
Exposure time	: 2 Years
Result	: negative

Species	: Mouse, male
Application Route	: Oral
Exposure time	: 2 Years
Result	: equivocal

**Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2020/10/10
4.0	2021/04/09	4944869-00004	Date of first issue: 2019/09/30

---

Species	: Rat, male and female
Application Route	: Oral
Exposure time	: 2 Years
Result	: negative

**Amlodipine Besylate:**

Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
Result	: negative

Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
Result	: negative

**Reproductive toxicity**

May damage the unborn child.

**Components:**
**Cellulose:**

Effects on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on foetal development	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative

**Olmesartan:**

Effects on fertility	: Test Type: Fertility Species: Rat Application Route: Oral Fertility: NOAEL: 1,000 mg/kg body weight Result: No effects on fertility
Effects on foetal development	: Test Type: Development Species: Rat Application Route: Oral Dose: 1000 milligram per kilogram Result: No teratogenic effects
	: Test Type: Development Species: Rabbit Application Route: Oral Dose: 1 milligram per kilogram Result: No teratogenic effects

**Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2020/10/10
4.0	2021/04/09	4944869-00004	Date of first issue: 2019/09/30

	Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: $\geq$ 1.6 mg/kg body weight Symptoms: Malformations were observed., Reduced body weight Result: Effects on postnatal development
Reproductive toxicity - Assessment	: Positive evidence of adverse effects on development from human epidemiological studies.

**Hydrochlorothiazide:**

Effects on fertility	: Test Type: Fertility Species: Rat, male and female Application Route: oral (feed) Fertility: NOAEL: 4 mg/kg body weight Result: Effects on fertility
	Test Type: Fertility Species: Mouse, male and female Application Route: oral (feed) Fertility: NOAEL: 100 mg/kg body weight Result: Effects on fertility
Effects on foetal development	: Test Type: Development Species: Mouse Application Route: Oral Developmental Toxicity: NOAEL: 3,000 mg/kg body weight Result: No teratogenic effects
	Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 1,000 mg/kg body weight Result: No teratogenic effects

**Amlodipine Besylate:**

Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Fertility: NOAEL: 10 mg/kg body weight Result: No effects on fertility
	Test Type: Fertility/early embryonic development Species: Rabbit Application Route: Ingestion Fertility: NOAEL: 25 mg/kg body weight Result: No effects on fertility
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion

# Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/10/10
4.0	2021/04/09	4944869-00004	Date of first issue: 2019/09/30

Developmental Toxicity: LOAEL: 10 mg/kg body weight  
Result: Effects on foetal development

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Ingestion  
Developmental Toxicity: NOAEL: 10 mg/kg body weight  
Result: No effects on foetal development

Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Ingestion  
Developmental Toxicity: LOAEL: 1.6 mg/kg body weight  
Result: Effects on foetal development  
Remarks: Maternal toxicity observed.

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

May cause damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.

### Components:

#### Hydrochlorothiazide:

Target Organs	:	Kidney, Parathyroid gland
Assessment	:	Causes damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

### Components:

#### Cellulose:

Species	:	Rat
NOAEL	:	>= 9,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days

#### Starch:

Species	:	Rat
NOAEL	:	>= 2,000 mg/kg
Application Route	:	Skin contact
Exposure time	:	28 Days
Method	:	OECD Test Guideline 410

#### Olmesartan:

Species	:	Rat
NOAEL	:	2,000 mg/kg
Application Route	:	Oral
Exposure time	:	24 Months

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version 4.0      Revision Date: 2021/04/09      SDS Number: 4944869-00004      Date of last issue: 2020/10/10  
Date of first issue: 2019/09/30

|| Remarks : No significant adverse effects were reported

### Hydrochlorothiazide:

|| Species : Rat, male and female  
|| LOAEL : 10 mg/kg  
|| Application Route : Oral  
|| Exposure time : 2 yr  
|| Target Organs : Kidney, Parathyroid gland

|| Species : Mouse, male and female  
|| NOAEL : 300 - 550 mg/kg  
|| Application Route : Oral  
|| Exposure time : 2 yr  
|| Remarks : No significant adverse effects were reported

|| Species : Dog  
|| : 50 - 200 mg/kg  
|| Application Route : Oral  
|| Exposure time : 9 Months  
|| Target Organs : Parathyroid gland

### Amlodipine Besylate:

|| Species : Rat  
|| NOAEL : 15 mg/kg  
|| Application Route : Oral  
|| Exposure time : 90 d  
|| Remarks : No significant adverse effects were reported

### Aspiration toxicity

Not classified based on available information.

### Components:

#### Hydrochlorothiazide:

|| No aspiration toxicity classification

### Experience with human exposure

### Components:

#### Olmesartan:

|| Eye contact : Symptoms: Eye irritation  
|| Ingestion : Symptoms: hypotension  
Remarks: May cause harm to the unborn child.  
Based on Human Evidence

#### Hydrochlorothiazide:

|| Eye contact : Symptoms: Eye irritation  
|| Ingestion : Symptoms: Dizziness, Headache, Fatigue, Nausea, Ab-

**Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2020/10/10
4.0	2021/04/09	4944869-00004	Date of first issue: 2019/09/30

dominal pain, hypotension, dry mouth, electrolyte imbalance, eye pain

**Amlodipine Besylate:**

Eye contact : Symptoms: Severe irritation

Ingestion : Symptoms: Nausea, Abdominal pain, Fatigue, Headache, Oedema, Palpitation

**12. ECOLOGICAL INFORMATION**
**Ecotoxicity**
Components:
**Cellulose:**

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

**Hydrochlorothiazide:**

Toxicity to fish : LC50 (*Pimephales promelas* (fathead minnow)): > 500 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): > 500 mg/l  
Exposure time: 48 h

**Amlodipine Besylate:**

Toxicity to fish : LC50 (*Pimephales promelas* (fathead minnow)): 2.7 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): 3.2 mg/l  
Exposure time: 48 h

Toxicity to algae/aquatic plants : IC50 (*Pseudokirchneriella subcapitata* (green algae)): 5.6 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

**Persistence and degradability**
Components:
**Cellulose:**

Biodegradability : Result: Readily biodegradable.

**Hydrochlorothiazide:**

Stability in water : Hydrolysis: 46.2 %(96 h)



# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 4.0      Revision Date: 2021/04/09      SDS Number: 4944869-00004      Date of last issue: 2020/10/10  
Date of first issue: 2019/09/30

---

### Bioaccumulative potential

#### Components:

#### **Amlodipine Besylate:**

Partition coefficient: n-octanol/water : log Pow: 3

#### **Mobility in soil**

No data available

#### **Hazardous to the ozone layer**

Not applicable

#### **Other adverse effects**

No data available

---

### 13. DISPOSAL CONSIDERATIONS

#### **Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

### 14. TRANSPORT INFORMATION

#### **International Regulations**

##### **UNRTDG**

Not regulated as a dangerous good

##### **IATA-DGR**

Not regulated as a dangerous good

##### **IMDG-Code**

Not regulated as a dangerous good

#### **Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

#### **National Regulations**

Refer to section 15 for specific national regulation.

---

### 15. REGULATORY INFORMATION

#### **Related Regulations**

##### **Fire Service Law**

Not applicable to dangerous materials / designated flammables.

##### **Chemical Substance Control Law**

Not applicable for Specified Chemical Substance, Monitoring Chemical Substance and Priority Assessment Chemical Substance.

---

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 4.0	Revision Date: 2021/04/09	SDS Number: 4944869-00004	Date of last issue: 2020/10/10 Date of first issue: 2019/09/30
----------------	------------------------------	------------------------------	---

---

### **Industrial Safety and Health Law**

#### **Harmful Substances Prohibited from Manufacture**

Not applicable

#### **Harmful Substances Required Permission for Manufacture**

Not applicable

#### **Substances Prevented From Impairment of Health**

Not applicable

#### **Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity**

Not applicable

#### **Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity**

Not applicable

#### **Substances Subject to be Notified Names**

Not applicable

#### **Substances Subject to be Indicated Names**

Not applicable

#### **Ordinance on Prevention of Hazards Due to Specified Chemical Substances**

Not applicable

#### **Ordinance on Prevention of Lead Poisoning**

Not applicable

#### **Ordinance on Prevention of Tetraalkyl Lead Poisoning**

Not applicable

#### **Ordinance on Prevention of Organic Solvent Poisoning**

Not applicable

#### **Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)**

Not applicable

#### **Poisonous and Deleterious Substances Control Law**

Not applicable

#### **Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof**

Not applicable

#### **High Pressure Gas Safety Act**

Not applicable

#### **Explosive Control Law**

Not applicable

#### **Vessel Safety Law**

Not regulated as a dangerous good

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 4.0	Revision Date: 2021/04/09	SDS Number: 4944869-00004	Date of last issue: 2020/10/10 Date of first issue: 2019/09/30
----------------	------------------------------	------------------------------	---

### Aviation Law

Not regulated as a dangerous good

### Marine Pollution and Sea Disaster Prevention etc Law

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Not classified as marine pollutant

### Narcotics and Psychotropics Control Act

Narcotic or Psychotropic Raw Material (Export / Import Permission)  
Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)  
Not applicable

### Waste Disposal and Public Cleansing Law

Industrial waste

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

## 16. OTHER INFORMATION

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemi-

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/10/10
4.0	2021/04/09	4944869-00004	Date of first issue: 2019/09/30

---

cal Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN